title: Inverse agonism at α2A adrenoceptors augments the hypophagic effect of sibutramine in rats.
abstract: Because the use of monoamine reuptake inhibitors as weight-reducing agents is limited by adverse effects, novel antiobesity drugs are needed. We studied acute effects of the noradrenaline (NA) and serotonin (5-HT) reuptake inhibitor sibutramine (SIB), alone and after pretreatment with α1- and α2-adrenoceptor (AR), and 5-HT1/2/7, 5-HT1B and 5-HT2C receptor antagonists in order to determine which ARs and 5-HT receptors act downstream of SIB on feeding and locomotion. Acute effects on caloric and water intake, meal microstructure and locomotion were assessed, using an automated weighing system and telemetry in male rats with restricted 18-h access to Western style diet. SIB 3 mg/kg reduced meal size and frequency, which suggests enhanced within- and postmeal satiety. Imiloxan (α2B-AR), WB4101 (α1-AR), SB-224289 (5-HT1B), and modestly BRL 44408 (α2A/D-AR) attenuated SIB's effect on meal size, suggesting that α2B- and α1-ARs and 5-HT1B receptors mediate within-meal satiety, with a modest role for α2A/D-ARs. Only prazosin (α1/2B/2C-AR) counteracted SIB's effect on meal frequency. At 3 mg/kg, SIB modestly increased locomotion. This effect was blocked by metergoline (5-HT1/2/7), WB4101 (α1-AR), and RX821002 (α2-AR). Interestingly, the α2-AR antagonists atipamezole and RX821002 enhanced SIB's effect on caloric intake, probably due to inverse agonistic actions at α2A-autoreceptors that further enhanced release of NA that regulates caloric intake. Thus, an inverse agonist of presynaptic α2A-ARs might beneficially enhance SIB's weight-reducing effect and offer novel treatment for obesity. All in all, the present data supports the ARs and 5-HT receptors involved in the effects of SIB on different aspects of caloric intake and locomotion.
authors.affiliation: Rudolf Magnus Institute of Neuroscience, Department of Neuroscience and Pharmacology, University Medical Center Utrecht, Utrecht, The Netherlands.
authors.forename: Sanna K
authors.initials: SK
authors.lastname: Janhunen
authors.forename: Esther M
authors.initials: EM
authors.lastname: van der Zwaal
authors.forename: Susanne E
authors.initials: SE
authors.lastname: la Fleur
authors.forename: Roger A H
authors.initials: RA
authors.lastname: Adan
mesh_terms: D000316:Adrenergic alpha-Agonists / Q000494:pharmacology* / Q000627:therapeutic use; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000818:Animals; D001067:Appetite Depressants / Q000494:pharmacology / Q000627:therapeutic use; D003503:Cyclobutanes / Q000494:pharmacology* / Q000627:therapeutic use; D002149:Energy Intake / Q000187:drug effects*; D005247:Feeding Behavior / Q000187:drug effects; D006963:Hyperphagia / Q000517:prevention & control*; D008124:Locomotion / Q000187:drug effects*; D008297:Male; D008711:Metergoline / Q000494:pharmacology; D009638:Norepinephrine / Q000378:metabolism; D009765:Obesity / Q000517:prevention & control*; D011224:Prazosin / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D018341:Receptors, Adrenergic, alpha-2 / Q000187:drug effects / Q000378:metabolism*; D011985:Receptors, Serotonin / Q000378:metabolism; D012528:Satiety Response / Q000187:drug effects; D017366:Serotonin Receptor Agonists / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000316:Adrenergic alpha-Agonists; D000317:Adrenergic alpha-Antagonists; D001067:Appetite Depressants; D003503:Cyclobutanes; D018341:Receptors, Adrenergic, alpha-2; D011985:Receptors, Serotonin; D017366:Serotonin Receptor Agonists; D008711:Metergoline; C058254:sibutramine; D009638:Norepinephrine; D011224:Prazosin